-
Lancet Oncol: Impact of neoadjuvant chemotherapy plus nintedanib on prognosis in patients with advanced muscle-invasive bladder cancer
Time of Update: 2022-05-21
For patients with muscle-invasive bladder cancer, the addition of nintedanib to the standard chemotherapy regimen is safe, but does not significantly improve the rate of pathological complete response .
-
Clin Oncol: Efficacy of Nintedanib + Docetaxel Third-Line Therapy After Progression on Second-Line Immunotherapy for Advanced Lung Adenocarcinoma
Time of Update: 2022-04-23
, the objective response rate was 50% (n=32; 1 complete response, 31 partial responses), and the disease control rate was 86% (n=55) . >Among 64 evaluable
-
Qilu Pharmaceutical sprints domestic nintedanib, the second nintedanib sales exceed 600%
Time of Update: 2022-03-06
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan) Source: Minet.
-
NEJM: Darolutamide in combination with androgen deprivation therapy-docetaxel in metastatic hormone-sensitive prostate cancer
Time of Update: 2022-03-04
However, it is unclear whether the combination of darolutamide, androgen deprivation therapy, and docetaxel improves survival in patients with metastatic hormone-sensitive prostate cancer .
-
Transl Lung Cancer Res: Efficacy of second-line docetaxel + ramucirumab in patients with metastatic NSCLC without driver mutation
Time of Update: 2022-03-04
Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation .
-
Front Oncol: A retrospective study comparing nab-paclitaxel and docetaxel as neoadjuvant therapy in patients with HER2- breast cancer
Time of Update: 2022-01-23
statistics Efficacy assessmentEfficacy assessmentAfter subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.
-
Eur Urol: Patient preference of the first-line chemotherapy drugs cabazitaxel and docetaxel in metastatic castration-resistant prostate cancer
Time of Update: 2021-12-24
They have similar efficacy in the first-line mCRPC treatment, but the safety status is differentRecently, researchers from France published an article in the "Eur Urol" magazine, evaluating the preference of docetaxel and cabazitaxel.
-
JCO: Quality of life for prostate cancer patients treated with docetaxel vs. abiraterone
Time of Update: 2021-12-04
Compared with docetaxel + standard androgen deprivation therapy, patients with locally advanced or metastatic hormone-sensitive prostate cancer treated with abiraterone acetate combined with prednisone or prednisone + standard androgen deprivation therapy within two years Reported quality of life is better.
-
Thorac Cancer: Retrospective analysis of the efficacy of docetaxel combined with ramucirumab
Time of Update: 2021-12-03
This retrospective study showed that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who received chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment .
-
Int J Cancer: Comparison of the efficacy of docetaxel + carboplatin vs epirubicin
Time of Update: 2021-10-10
was 33. 3% (1/3) in the DCb group and 100% in the EC-D group (p = 0. 400) . 27 patients in the DCb group achieved pCR (61. 4%, 95% CI 47
-
Arthritis & Rheumatology: Nintedanib in the treatment of patients with systemic sclerosis-related
Time of Update: 2021-09-28
Although the decline of FVC in patients with SSc-ILD is still difficult to predict, nintedanib is effective in reducing the annual progression rate of ILD in each subgroup according to baseline ATA status, SSc subtype and mRSS .
-
Lung Cancer: Efficacy of docetaxel vs docetaxel + erlotinib in the treatment of relapsed advanced
Time of Update: 2021-09-18
/>0 8. 6) and 4. 7 months (95% CI: 3. 2 8. 6) (adjusted HR=3. 67, 95% CI: 1. 46 9. 27, p = 0. 004) . The 1-year survival rates
-
What problems should be paid attention to when using docetaxel
Time of Update: 2021-09-04
Some patients, when receiving treatment, need dexamethasone for anti-allergic treatment in advance, which can reduce the adverse effects of docetaxel on the body .
-
Eur J Cancer: Paclitaxel is significantly better than docetaxel in fluoropyrimidine and platinum refractory esophageal squamous cell carcinoma!
Time of Update: 2021-08-04
In patients with esophageal squamous cell carcinoma refractory to first-line fluoropyrimidine and platinum-based chemotherapy, compared with DTX, PTX showed significantly better efficacy and more controllable safety .
-
) with or without docetaxel in the treatment of non-metastatic, adverse-risk prostate cancer: a prospective randomized study
Time of Update: 2021-08-01
Therefore, foreign scholars have carried out prospective studies to evaluate the efficacy of docetaxel combined with androgen deprivation therapy (ADT) + radiotherapy (RT) on newly diagnosed male non-metastatic prostate cancer patients with adverse risks .
-
Docetaxel injection, a subsidiary of Osaikang, passed the consistency evaluation of generic drugs
Time of Update: 2021-05-23
for marketing in the United States; so far, has been listed in many countries, for breast cancer, non-small cell lung cancer, prostate cancer, Gastric cancer and head and neck
-
J Thorac Oncol: The efficacy of nano-paclitaxel vs docetaxel in the treatment of patients with advanced NSCLC
Time of Update: 2021-05-20
For patients with previously treated advanced NSCLC, nab-paclitaxel is not inferior to docetaxel in terms of overall survival.
-
Hengrui Medicine: Docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs
Time of Update: 2021-05-03
Docetaxel is a paclitaxel anti-tumor drug, which plays an anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function .
-
Hengrui Medicine: Docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs
Time of Update: 2021-04-27
On March 25, Hengrui Pharmaceutical announced that the company's docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs.
-
Hengrui Medicine: Docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs
Time of Update: 2021-03-29
Docetaxel is a paclitaxel anti-tumor drug, which plays an anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function .
